Introduction
============

Parkinson's disease (PD) is a common movement disorder and the second most prevalent neurodegenerative disorder worldwide, that affects nearly 2% of the elderly population. PD is characterized by loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and consequently reduced dopamine (DA) levels in the basal ganglia, causing motor dysfunction (**Figure [1](#F1){ref-type="fig"}**). Lewy bodies, intracellular proteinaceous inclusions, are the pathological hallmark within PD brains. Lewy bodies contain fibrillar α-synuclein among other proteins ([@B174]). It is evident that the immune system is involved in PD risk by genome-wide association studies (GWAS), implicating the human leukocyte antigen (HLA) locus with sporadic PD ([@B71]) and, as well, by the neuropathology in PD brains demonstrating highly activated microglial and T-cells ([@B118]; [@B85]). Several inflammatory markers have been identified in SNpc of PD brains including cytokines and neurotrophins ([@B129]; [@B83]). Also, widespread microglial activation is a concomitant in PD neuropathology ([@B64]). A meta-analysis of anti-inflammatory drug trials revealed an association between non-steroidal anti-inflammatory drugs (NSAIDs) use and reduced risk for developing PD possibly implicating neuroinflammatory processes in the disease ([@B58]). Evidence supports the conclusion that microglia, the brain resident macrophage-like immune cells, participate in the inflammatory response of the disease ([@B153]; [@B110]; [@B124]). In addition, other observations implicate peripheral immune cells in PD ([@B164]; [@B57]; [@B29]). Together these data indicate that inflammation and microglial activation contribute to the in pathogenesis of PD. Hence, immunomodulation might be a possible therapeutic avenue for PD.

![The nigrostriatal dopaminergic pathway and motor basal ganglia circuitry in Parkinson's disease (PD) brain. **(A)** In the nigrostriatal pathway, the striatum, Str (caudate nucleus and putamen), receives dopaminergic innervation from the substantia nigra pars compacta (SNpc) in the midbrain. **(B)** A schematic showing normal motor basal ganglia circuitry (left side) and its irregularities in PD brain (right side), adapted from ([@B11]). *Normal brain (left)*: The dopaminergic afferent neurons from the SN synapse with GABAergic neurons which display either D1 or D2 dopaminergic receptors. These GABAergic populations project directly (red arrows) or indirectly (blue arrows; through globus pallidus externa, GPe, and subthalamic nucleus, STN) to globus pallidus interna (GPi). The output from the GPi (green arrows) to the thalamus is inhibitory and modulates normal motor function. *PD brain (right)*: The loss of dopaminergic neurons in the SN and depletion of striatal dopamine leads to elevated inhibitory output from the GPi to the thalamus causing reduction in normal motor function. Inhibitory and excitatory inputs are marked as (--) and (+), respectively. The intensity of the inputs is marked with thickness of lines. Str, striatum; Th, thalamus.](fnagi-09-00176-g001){#F1}

The distribution of microglial M1/M2 phenotypes depends on the stage and severity of the disease. Understanding stage-specific switching of microglial phenotypes and the capacity to manipulate these transitions within appropriate time windows might be beneficial for PD therapy. In this review, we will outline different microglial activation states and provide evidence of M1/M2 activation states in PD. We will also discuss how manipulation of M1/M2 activation may be of potential therapeutic value.

Microglia Functions
===================

In the central nervous system (CNS), the innate immune response is predominantly mediated by microglia and astrocytes. Microglia play a vital role in both physiological and pathological conditions. Tissue-specific macrophages can be found in most tissues of the body, whereas microglia are present distinctly in the brain. Microglia are derived from primitive yolk sac myeloid progenitors that seed the developing brain parenchyma ([@B3]; [@B66]). Microglia represent 10--15% of the total population of cells within the brain and manifest different morphologies across anatomic regions ([@B105]; [@B122]). Microglia appear to be involved in several regulatory processes in the brain that are crucial for tissue development, maintenance of the neural environment and, response to injury and promoting repair. Similar to peripheral macrophages, microglia directly respond to pathogens and maintain cellular homeostasis by purging said pathogens, as well as dead cells and pathological gene products ([@B63]; [@B19]; [@B177]; [@B187]; [@B138]; [@B143]). In addition, microglial function can be altered by interactions with neurons, astrocytes, migrating T-cells, and the blood--brain barrier itself ([@B69]).

Under physiological conditions, microglia acquire a neural-specific, relatively inactive phenotype ([@B165]) where they sample and inspect the local environment and other brain cells types ([@B40]; [@B134]). In a healthy brain, resting quiescent microglia exhibit a ramified morphology, with relatively long cytoplasmic protrusions, a stable cell body and little or no movement (**Figure [2](#F2){ref-type="fig"}**). Quiescent microglia extend processes into their surrounding environment ([@B134]). This resting stage is partly maintained by signals conveyed by neuronal and astrocyte-derived factors ([@B132]; [@B156]). The maintenance of this inactive state is regulated by several intrinsic factors like Runx1 (Runt-related transcription factor 1) and Irf8 (Interferon regulatory factor 8), and extrinsic factors such as TREM2 (triggering receptor also expressed on myeloid cells-2), chemokine CX3CR1 and CD200R ([@B94]). In the normal CNS environment, healthy neurons provide signals to microglia via secreted and membrane bound factors, such as CX3CL1, neurotransmitters, neurotrophins and CD22 ([@B180]; [@B55]; [@B111]; [@B149]). In addition, microglia express elevated levels of microRNA-124 which in turn reduces CD46, MHC-II (major histocompatibility complex II) and CD11b, to maintain the quiescent state ([@B34]).

![Schematic of microglial polarization states and function. In normal physiological conditions microglia acquire the surveillance phenotype to maintain all CNS cell types including neurons. To maintain this surveillance state, microglia secrete several factors including colony stimulating factor 1 receptor (CSF1R), signal regulatory protein CD172 (SIRP1A), chemokine CX3CL1 and CD200R. Upon classical activation when triggered by LPS, IFN-γ, or GM-CSF microglia acquire M1 pro-inflammatory phenotype leading to neurotoxicity by secreting several pro-inflammatory substances (for detailed list, see **Table [1](#T1){ref-type="table"}**). When activated alternatively by IL-1, IgG, or IL-10 microglia attain M2 anti-inflammatory state prompting neuroprotection through secretion of variety of substances (for detailed list, see **Table [1](#T1){ref-type="table"}**). Arg1, arginase 1; CCL, chemokine (C-C motif) ligand; CD, cluster of differentiation; CSF1R, colony stimulating factor 1 receptor; CXCL, chemokine (C-X-C motif) ligand; Fizz1, found in inflammatory zone; IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon-γ; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; MAMPs, microbe-associated molecular patterns; MHC-II, major histocompatibility complex II; SIRP1A, signal regulatory protein CD172; SOCS3, suppressor of cytokine signaling-3; TNF-α, tumor necrosis factor-α; Ym1, chitinase-like protein.](fnagi-09-00176-g002){#F2}

Microglial Activation: The Dual Roles of Microglia
==================================================

As peripheral macrophages respond to endogenous stimuli promoting both pathogenic and protective functions, so do microglia. Upon exposure to endogenous stimuli microglia become activated. Among the gene products released by microglia are various substances including pro-inflammatory cytokines, neurotoxic proteins, chemokines, anti-inflammatory cytokines, and neurotrophic factors ([@B112]; [@B12]; [@B8]; [@B130]). Microglia also display signaling immunoreceptors such as Toll-like receptors (TLRs), scavenger receptors (SRs), nucleotide binding oligomerization domains (NODs) and NOD-like receptors ([@B155]). Fundamentally, the two polar states of microglia, the M1 and M2 phenotypes are associated phenomenologically with injury and homeostasis, respectively (as described below). Differential states of microglial activation within an injured tissue evolve during an inflammatory epoch ([@B70]).

M1 Polarization State
---------------------

When classically activated, microglia acquire the M1 phenotype, characterized by pro-inflammatory and pro-killing functions that serve as the first line of defense. In M1 microglial activation state both secreted factors and cellular markers are dysregulated (**Table [1](#T1){ref-type="table"}**). During M1 polarization (driving from another, often resting state), microglia release pro-inflammatory cytokines: interleukin-1β (IL-1β), IL-6, IL-12, IL-17, IL-18, IL-23, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and nitric oxide, and chemokines: CCL2 ([@B112]; [@B90], [@B91]; [@B109]; [@B8]; [@B130]). Also upon M1 activation microglia appear to present phenotypic markers: inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), MHC-II, and CD86 (cluster of differentiation marker 86) ([@B31]; [@B54]) and, other substances including reactive oxygen species (ROS), reactive nitrogen species, and prostaglandin E2 ([@B8]; [@B130]). These orchestrated processes are to purge foreign pathogens and polarize T-cells to elicit an adaptive immune response.

###### 

Microglial polarization states and substances produced.

  Activation type/function                                          Source                                           Substances produced                                                                                                       Reference
  ----------------------------------------------------------------- ------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------
  M1 (classical activation): pro-inflammatory and pro-killing       LPS, IFN-γ                                       *Cytokines*: IL-1β, IL-6, IL-12, IL-17, IL-18, IL-23, TNF-α                                                               [@B112]; [@B90] [@B91]; [@B109]; [@B8]; [@B31]; [@B54]; [@B130]
                                                                                                                     *Markers*: CD86, MHC-II                                                                                                   
                                                                                                                     *Chemokines*: CCL2                                                                                                        
                                                                                                                     *Metabolic enzyme/redox molecules*: iNOS, COX-2, reactive oxygen species and reactive nitrogen species prostaglandin E2   
                                                                                                                                                                                                                                               
  M2a (alternative activation): tissue repair and phagocytosis      IL-4, IL-13                                      *Cytokines*: IL-10                                                                                                        [@B112]; [@B109], [@B8]; [@B31]; [@B54]; [@B130]
                                                                                                                     *Markers*: CD206, SR-A1, SR-B1, Arg1, Ym1, Fizz1                                                                          
                                                                                                                     *Others*: extracellular matrix proteins, PPAR                                                                             
  M2b (alternative activation): recruitment of regulatory T cells   Fcγ receptors, TLRs and immune complexes (IgG)   *Cytokines*: IL-1β, IL-6, IL-10, TNF-α                                                                                    
                                                                                                                     *Markers*: CD86, MHC-II                                                                                                   
                                                                                                                     *Others*: SOCS3, COX-2, Sphk                                                                                              
  M2c (alternative activation): anti-inflammatory and healing       IL-10, TGF-β and glucocorticoids                 *Cytokines*: IL-10, TGF-β                                                                                                 
                                                                                                                     *Markers*: CD163                                                                                                          
                                                                                                                                                                                                                                               

Arg1, arginase 1; CCL, chemokine (C-C motif) ligand; CD, cluster of differentiation; COX-2, cyclooxygenase-2; Fizz1, found in inflammatory zone; IFN-γ, interferon-γ; IL, interleukin; iNOS, inducible nitric oxide synthase; MHC-II, major histocompatibility complex II; SOCS3, suppressor of cytokine signaling-3; Sphk, sphingosine kinase; SR-A1, scavenger receptor class A1; SR-B1, scavenger receptor class B1; TGF, transforming growth factor; TNF-α, tumor necrosis factor-α; Ym1, chitinase-like protein.

The M1 phenotype of microglia can be induced in experimental models using microbe-associated molecular pattern molecules such as lipopolysaccharide (LPS), an endotoxin present in the cell membranes of Gram-negative bacteria, or others related to infections such as IFN-γ (**Figure [3](#F3){ref-type="fig"}**; [@B109]; [@B13]). Similarly, an aseptic inflammatory response also occurs after exposure to trauma or ischemia-reperfusion injury or chemical injury.

![Overview of microglial M1 and M2 signaling in neurodegeneration, and potential targets for neuroprotection. The left side of the figure compartment shows M1 microglial phenotype and its major signaling pathways. LPS binds to TLR4 on the cell surface which is coupled to MD2 (TLR/MD2) with participation of co-receptors CD14 and LBP (LPS-binding protein), activates interleukin-1 receptor-associated kinases (IRAKs) through MyD88 and TRIF that causes translocation of transcription factors such as NF-κB, STAT5, activator protein-1 (AP1), and interferon regulatory factors (IRFs) to the nucleus. M1 activation by IFN-γ occurs through IFN-γ receptors 1 and 2 (IFN-γR1/2) leading to the recruitment of Janus kinase 1 and 2 (JAK1/2) that phosphorylate and translocate STAT1 and IRFs to the nucleus. M1 activation stimulation through granulocyte-macrophage colony-stimulating factor (GM-CSF) occurs when GM-CSF binds to its receptor GM-CSF-R, which activates rat sarcoma oncoproteins (RAS), JAK2, and SFK, and causes translocation of STAT5 to the nucleus. The translocation of NF-κB, STAT1, STAT5, AP1, and IRFs to the nucleus causes upregulation of intracellular iNOS and cell surface markers (CD86, CD16/32, MHC-II). M1 stimulation also causes transcriptional upregulation of M1-associated pro-inflammatory cytokines (IL-1β, IL-6, IL-12, TNF-α) and chemokines (CCL2, CXCL10). The right side of the figure compartment shows various M2 microglial phenotypes and major signaling pathways involved. M2 activation can be classified into M2a, M2b, and M2c. M2a state is induced mainly by IL-4. IL-4 binds to IL-4R, which stimulates JAK1 or JAK3 that causes translocation of STAT6 to the nucleus leading to transcription of M2a-associated genes including IL-10, cell surface markers (CD206, scavenger receptors, SRs), and intracellular components such as suppressor of cytokine signaling 3 (SOCS3), Ym1 (chitinase-like protein) and Fizz1 (found in inflammatory zone). The M2b activation state, which has some M1 response characteristics, is stimulated when TLRs fuse Fcγ receptors, which then bind to IgG (B cells) to derive the M2b phenotype. M2b activation results in secretion of IL-10 and, cell surface markers (CD86, MHC-II). M2c activation is induced by IL-10 which stimulates the IL-10 Receptor 1 and 2 subunits that activates JAK1 leading to the translocation of STAT3 to the nucleus. STAT3 translocation inhibits M1-associated pro-inflammatory cytokines and upregulation of IL-10, TGF-β and the cell surface marker CD206. M2c state plays an important role in immunoregulation, matrix deposition and tissue remodeling. The bottom half of the figure shows potential therapeutic microglial targets for neuroprotection. (1) JAK/STAT inhibition: M1 phenotype is induced via the JAK/STAT signaling pathway and inhibition of this pathway may suppress the downstream M1-associated pro-inflammatory genes. (2) Histone deacetylase (HDAC) inhibitors: Histone acetylation is increased in M1 state that may lead to the expression and release of pro-inflammatory cytokines. HDAC inhibitors prevent neurodegeneration by shifting microglia toward protective M2 phenotype and anti-inflammatory mechanisms. (3) Microglia-produced high-mobility group box-1 (HMGB1) inhibitors: HMGB1 is a pro-inflammatory cytokine released by microglia which is toxic to neurons. HMGB1 inhibitors show neuroprotection by binding to HMGB1 and inhibiting its cytokine-like activity. (4) Alteration of M1/M2 balance: These agents promote the shift M1 pro-inflammatory phenotype toward protective M2 phenotype, and also exhibit neuroprotection by counteracting excessive pro-inflammatory M1 cytokines. (5) Adenosine monophosphate-activated protein kinase (AMPK) activators: AMPK activators act by inhibiting the expression of pro-inflammatory cytokines and iNOS by reducing NF-κB activation. (6) Peroxisome proliferator-activated receptor (PPAR) agonists: PPAR agonists exhibit neuroprotection by upregulating AMPK and protective genes, reducing oxidative damage, maintaining mitochondrial function and anti-inflammatory mechanisms. (7) Glycogen synthase kinase-3 β (GSK3β) inhibitors: GSK3β regulate microglial migration, inflammation, and neurotoxicity through astrocytes. GSK3β inhibitors decrease inflammation by reducing iNOS expression and release of nitric oxide (NO). (8) Endocannabinoid system targets: Agents that target the endogenous cannabinoid ligands anandamide and 2-arachidonoylglycerol (2-AG) increase TGF-β, arginase 1 and glial cell line-derived neurotrophic factor (GDNF), and reduce iNOS and COX-2, expression. AICAR, 5-amino-4-imidazole carboxamide riboside; GA, glatiramer acetate; HO-1, heme oxygenase 1; MMBO, 2-methyl-5-methylsulfinylphenyl-1-benzofuranyl-1,3,4-oxadiazole; NP-12, tideglusib; NQO1, NAD(P)H quinone dehydrogenase 1; Nrf2, nuclear erythroid 2-related factor 2; ARE, antioxidant response element; SOD1, superoxide dismutase 1; TSA, trichostatin A.](fnagi-09-00176-g003){#F3}

IFN-γ utilizes the JAK/STAT (Janus kinase/signal transducer and activator of transcription) signaling pathway to activate the M1 phenotype. M1 activation by IFN-γ occurs through activation of IFN-γ receptors 1 and 2 (IFN-γR1/2) leading to JAK1/2 activation, phosphorylation and the nuclear translocation of STAT1 along with interferon regulatory factors (IRFs). This signaling cascade promotes expression of M1-associated cytokines, chemokines, and other genes ([@B82]; [@B13]).

LPS induces M1 activation via TLRs, which recognize specific patterns of microbial macromolecules. LPS binds to TLR4 on the cell surface that is coupled to MD2 (myeloid differentiation protein 2) (TLR/MD2) with participation of co-receptors CD14 and LBP (LPS-binding protein). LPS binding to TLR4 results in activation through MyD88 (myeloid differentiation primary response protein 88) and TRIF (TIR domain-containing adaptor inducing IFN-β), and transcription factors such as NF-κB (nuclear factor kappa B), STAT5, and IRFs ([@B183]). This causes transcriptional upregulation of M1-associated cytokines, chemokines and other genes. Alternative M1 activation stimulation through granulocyte-macrophage colony-stimulating factor (GM-CSF) has been demonstrated recently ([@B101]). However, unlike LPS and IFN-γ, GM-CSF is reported to instigate pleomorphic activation states that shows characteristics of both M1 and M2 phenotypes ([@B196]). **Figure [3](#F3){ref-type="fig"}** (left side) provides further details on M1 activation.

M2 Polarization State
---------------------

The alternative M2 microglial activation state is involved in various events including immunoregulation, inflammation dampening, and repair and injury resolution. M2 microglia is morphologically characterized by enlarged cell bodies (**Figure [2](#F2){ref-type="fig"}**). M2 microglial activation produces an array of mediators such as anti-inflammatory cytokines, extracellular matrix proteins, glucocorticoids, and other substances.

Presently, the mechanism of M2 activation in microglia is poorly understood compared to macrophages. It is believed that microglia can develop diverse M2 phenotypes similar to macrophages ([@B127]; [@B78]; [@B167]). The characteristics of M2 polarization of microglia parallel that of the macrophages ([@B31]; [@B56]) producing IL-4 and IL-10 stimulation through Arg1 (arginase 1), Ym1 (chitinase-like protein), Fizz1 (found in inflammatory zone), and PPAR (peroxisome proliferator-activated receptor) ([@B121]). M2 macrophage activation is sub-classified into M2a, M2b, and M2c, and these activation states may be envisaged to microglia ([@B13]; **Figure [3](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). The M2a state is induced by IL-4 or IL-13 and, is associated with tissue repair and phagocytosis. IL-4 binds to different receptor pairs, which stimulate JAK1 or JAK3 and activates STAT6 leading to transcription of M2a-associated genes including CD206, suppressor of cytokine signaling 3 (SOCS3) and SRs. The M2b activation state is stimulated by engagement of TLRs and the IL-1 receptor, and is involved in the recruitment of regulatory T cells. Activated TLRs fuse Fcγ receptors, which then bind to IgG (B cells) to derive the M2b phenotype. M2b activation results in secretion of IL-10, CD86 (on cell surface) and MHC-II. M2c activation state is induced by IL-10 and glucocorticoid hormones, and is involved in anti-inflammatory and healing functions. IL-10 stimulates the IL-10R1 and IL-10R2 which activate JAK1 leading to the translocation of STAT3 into the nucleus. STAT3 translocation suppresses most of the M1-associated pro-inflammatory cytokines ([@B54]; [@B120]). Overall, it is considered that the M2 activation promotes healing and tissue repair whereas the M1 activation state is the first line of defense with pro-killing functions. Please see **Figure [3](#F3){ref-type="fig"}** (right side) for details on M2 activation.

Polarization Transitions
------------------------

The transition from the M1 pro-inflammatory state to the regulatory or anti-inflammatory M2 phenotype is thought to assist improved functional outcomes and restore homeostasis ([@B140]). Recently, histone H3K27me3 demethylase Jumonji was shown to be essential for M2 polarization and down-regulation of the M1 phenotype ([@B184]). The induction of M1 phenotype is a relatively standard response during injury. For peripheral immune cells it is thought that M1 polarization is terminal and the cells die during the inflammatory response ([@B140]). Although a shift from M1 to the M2 phenotype is considered rare for peripheral immune cells, the microglia *can shift* from M1 to M2 phenotype when exposed to IL-10, glatiramer acetate, beta interferons, PPARγ agonists and other molecules discussed in the later section. Although, the M1 and M2 microglial phenotypes vastly differ in their function, different subpopulations in an injury environment may express specific phenotypes resulting in concurrent expression of M1- and M2-related factors or mixed M1/M2 phenotypes ([@B206]; [@B146]; [@B191]). The potential to pharmacologically promote a microglial M1 to M2 shift may have therapeutic implications in the setting of neurodegenerative diseases associated with neuroinflammation.

Microglia-Mediated Inflammation in PD
=====================================

The involvement of innate immunity in PD was first proposed by [@B118] when brain from PD patients showed high levels of reactive microglia that were positive for human leukocyte antigen-D related (HLA-DR) in the substantia nigra and putamen. GWAS indicate that variants in the HLA region are linked to sporadic PD ([@B71]; [@B79]). Activated microglia in PD brain appear responsible for exacerbating neurodegeneration ([@B119]), and the exposure of human neuromelanin discharged from dead DA neurons cause chemotaxis and increases the pro-inflammatory substances in microglial cultures ([@B198]). M1 activation-associated inflammatory markers such as MHC-II ([@B85]), TNF-α and IL-6 ([@B14]; [@B85]) have been reported in patients with PD. Recent positron emission tomography (PET) studies show that PD patients have cortical microglial activation and lower brain glucose metabolism early in the disease, and imply that microglial activation may be a contributing factor in the disease progression ([@B49]). PET with inflammatory ligands show elevation in several areas of the basal ganglia involved in PD pathology ([@B64]; [@B49]; [@B84]). TLR2 is increased in postmortem PD brain tissue, which correlates with pathological α-synuclein deposition. The neuronal TLR2 rather than glial expression of TLR2 is significantly elevated in PD brain and correlates with disease progression. In addition, TLR2 is strongly localized in α-synuclein positive Lewy bodies ([@B47]). These observations highlight the crucial role of neuroinflammation in PD pathogenesis.

Peripheral Inflammation in PD
=============================

"The dual hit theory" of PD development states that a neurotropic pathogen enters the brain by nasal and/or gastric route by axonal transport, the latter via the vagus nerve ([@B16]; [@B75]). There is evidence that some forms of α-synuclein can be transmitted from the gut to the brain ([@B141]; [@B189]; [@B81]). Instillation of rotenone into the rodent stomach exhibits progressive pathological α-synuclein inclusions in the enteric nervous system, the vagus nerve and subsequently in the brain stem ([@B141]). Vagotomy prevents transport of pathological proteins from the gut to CNS ([@B147]; [@B142]). A recent study in Danish patients reveals that those who underwent full truncal vagotomy had lower risk for PD, suggesting that the vagus nerve might be critically involved in PD pathogenesis ([@B181]). Another clinical study reports that serum levels of the pro-inflammatory cytokine IL-1β discriminated asymptomatic LRRK2-G2019S carriers from controls and suggests that peripheral inflammation is greater in a percentage of subjects carrying LRRK2-G2019S mutation ([@B48]).

The major peripheral immune cells, T-lymphocytes and B-lymphocytes, are not found in the CNS in normal biological conditions. However, with peripheral inflammation such as infection or injury, blood monocytes, and tissue-resident immune cells are activated and secrete variety of pro-inflammatory mediators including TNF-α, IL-6, and IL-1β. These pro-inflammatory mediators cross the blood--brain barrier leading to the activation of brain resident microglia, which then triggers a neuroinflammatory cascade. The blood--brain barrier is considered to be impermeable to external pathogens and circulating macrophages, hence serving as an additional line of defense to the CNS. Nevertheless, damage to the integrity of the blood--brain barrier renders the brain vulnerable. PET studies on patients with PD reveal dysfunctional blood--brain barrier ([@B99]). Damage to the blood--brain barrier in rats induce degeneration of dopaminergic neurons in the substantia nigra and activate glial cells ([@B159]). CD8^+^ and CD4^+^ T cells are observed in the postmortem human PD brain and MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of PD during its neurodegenerative phase suggesting T cell-mediated dopaminergic toxicity as a putative mechanism ([@B18]). Moreover, rats with ulcerative colitis are more susceptible to LPS-induced dopaminergic neuron loss, blood--brain barrier permeability, microglial activation, and generation of pro-inflammatory mediators suggesting that peripheral inflammation may increase the risk of PD ([@B190]). A recent study in the acute MPTP mouse model where nigrostriatal pathologies are not robust show that administration of chemokines \[regulated on activation, normal T cell expressed and secreted (RANTES) and eotaxin\] that facilitate T cell trafficking can lead to marked nigral α-synuclein pathology, loss of dopaminergic neurons and striatal neurotransmitter depletion, glial-associated inflammation, and motor impairments. However, systemic administration of pro-inflammatory cytokines, TNF-α and IL-1β, did not induce such disease pathologies in this acute MPTP model ([@B27]). Taken together these studies suggest a more direct link between peripheral inflammation and, potential to elicit and affect the timing of PD onset.

Genetic Factors Linked to Inflammation in PD
============================================

Mutations in leucine-rich repeat kinase (LRRK2, PARK8) are linked with autosomal dominantly inherited PD and is the greatest known genetic contributor to PD. LRRK2-G2019S mutation in the kinase domain is the most common mutation in both familial and sporadic form of the disease ([@B68]). GWAS show that the genetic locus containing the LRRK2 gene presents a risk factor for sporadic PD ([@B171]). Interestingly, GWAS implicate LRRK2 as a major susceptibility gene in inflammatory bowel diseases that involve chronic inflammation ([@B6]; [@B108]). LRRK2 is reported to be a target gene for IFN-γ, a M1-activation-associated pro-inflammatory cytokine. LRRK2 expression is elevated in human intestinal tissue of patients with Crohn's disease inflammation ([@B62]). LRRK2 shows high expression in immune cells including microglia and inhibition of LRRK2 function reduces M1-associated inflammation and PD neurodegeneration ([@B123]; [@B39], [@B38]; [@B162]). Collectively, these studies point toward the importance of LRRK2 function in M1-activation responses in PD animal models ([@B124]).

Three different missense mutations (A530T, A30P, and E46K) within the open reading frame or duplication or triplication of the wild type α-synuclein gene (SNCA, PARK1) are associated with autosomal dominant PD ([@B150]; [@B100]; [@B172]; [@B203]). Fibrillar forms of α-synuclein are a major component of the Lewy bodies in both sporadic and familial PD. α-Synuclein, a cytoplasmic protein, can be expressed in microglia and may be involve modulation and pre-sensitization of microglial activation ([@B5]; [@B161]; [@B204]). Most activated microglia in PD patient brains are associated with α-synuclein-positive Lewy neurites ([@B85]), and there is significant correlation between the expression of M1 activation-associated marker MHC-II and α-synuclein deposition in the substantia nigra of PD patients ([@B36]). Previous studies by our group and others using *in vitro* and animal models show that both wild type and mutant α-synuclein can modulate microglial activation leading to neuroinflammation. Our previous work shows that α-synuclein activates microglia in a dose-dependent manner in cultured cells and an early microglial activation event occurs in mice overexpressing wild type α-synuclein ([@B179]). Another study reveals that mutant α-synuclein can directly interact with cultured microglia releasing pro-inflammatory substances and mice overexpressing mutant α-synuclein exhibit microglial activation at a very early age ([@B178]). In addition, we show that misfolded α-synuclein induces microglial activation and the release of pro-inflammatory cytokines in BV2 microglial cells ([@B10]). Overexpression of α-synuclein in BV2 microglial cells increase pro-inflammatory mediators (TNF-α, IL-6, nitric oxide, COX-2) and induce a reactive microglial phenotype ([@B160]). Interestingly, TLR4, which is activated by LPS to induce microglial M1-phenotype, is reported to mediate α-synuclein-induced microglial phagocytosis, upregulation of pro-inflammatory cytokine expression and ROS generation in primary microglial cultures ([@B52]). In addition, α-synuclein is reported to play a crucial role in modulating microglial activation states in postnatal brain derived microglial cultures ([@B4]). Moreover, neuroinflammation with activated microglia and increased pro-inflammatory cytokines (TNF-α, IL-1β, IFN-γ) precedes α-synuclein-mediated neuronal cell death in rats delivered with mutant A53T human α-synuclein ([@B32]). There is a rich literature on the role of α-synuclein in the progression of PD by inducing microglia activation and neuroinflammation which is reviewed elsewhere ([@B204]).

In addition, genes linked to familial recessive PD including phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1, PARK6) and DJ-1 (PARK7) are strongly associated with neuroinflammation. Deletion of PINK1 or DJ-1 causes aberrant expression of genes involved in p38 MAP kinase/NF-κB signaling pathways that regulate innate immune responses in disease models ([@B35]; [@B2]).

Inflammation in PD Animal Models
================================

LPS, a bacterial endotoxin from cell wall of Gram-negative bacteria, induces M1-polarization of microglia through activation the pattern recognition TLR4. LPS administration into rodent brains recapitulate certain characteristics of sporadic PD including progressive degeneration of nigrostriatal dopaminergic pathway and motor anomalies. A single injection or 2-week infusion of LPS in the supranigral region in rat brain causes rapid microglia activation followed by dose and time-dependent degeneration of nigrostriatal dopaminergic circuitry ([@B25]; [@B59]; [@B106]; [@B46]). Direct injection of LPS shows dopaminergic neuron loss specifically in SNpc but not in ventral tegmental area which also houses dopaminergic neurons ([@B98]). This specific neurotoxicity in SNpc may be attributed to the high proportion of microglia in SNpc compared with other brain regions ([@B105]), that may trigger inflammatory events leading to the degeneration of nigrostriatal pathway. Moreover, injection of a TLR3 agonist in the substantia nigra of adult rats induces a sustained inflammatory reaction in the substantia nigra (SN) and dorsolateral striatum, and also increases the vulnerability of midbrain dopaminergic neurons to a subsequent neurotoxic trigger ([@B43]).

A transgenic mouse PD model that overexpresses human wild type α-synuclein, Thy1-aSyn (line 61) ([@B30]), shows microglial activation as early as 1 month and persists until 14 months of age ([@B195]). Increased levels of TNF-α, TLRs (TLR1, TLR2, TLR4, and TLR8), MHC-II, CD4, and CD8 are observed in Thy1-aSyn mice at different ages. This study also reveals that despite expression of α-synuclein globally in the brain only the regions containing cell bodies and axon terminals of nigrostriatal pathway show early inflammatory response. Another transgenic rodent model overexpressing doubly mutated (A53T and A30P) human α-synuclein show glial mitochondria alterations ([@B166]). In a PD mouse model that overexpresses human α-synuclein by recombinant adeno-associated virus vector, serotype 2 (rAAV2)-mediated transduction in the SNpc, inflammatory responses such as microglial activation and greater infiltration of B and T lymphocytes are observed in addition to dopaminergic neurodegeneration ([@B186]). These studies show that animal models overexpressing human or mutant α-synuclein exhibit microglial activation and neuroinflammation.

MPTP, a meperidine analog byproduct, is a neurotoxin that causes acute and irreversible human parkinsonism ([@B41]; [@B103]). MPTP is a lipophilic compound that can actively cross the blood--brain barrier and gets oxidized by monoamine oxidase to the toxic cation, MPP^+^ (1-methyl-4-phenylpyridinium) in the glial cells ([@B104]; [@B115]). MPP^+^ utilizes the DA transporter (DAT) to get into the dopaminergic neurons. MPP^+^ accumulates in the mitochondria and inhibits the mitochondrial complex I in the electron transport chain (ETC) ([@B133]; [@B154]) resulting in reduced ATP levels and production of ROS ([@B74]; [@B26]; [@B72]; [@B152]; [@B51]; [@B145]). In animal models, MPTP induces inflammatory responses that lead to neurodegeneration. MPTP causes microglial activation and an increase in M1-associated pro-inflammatory cytokines such as IL-6, IFN-γ and TNF-α. The glial response to MPTP is reported to peak before dopaminergic neuron loss ([@B37]; [@B173]). In support of these findings, it is reported that mice lacking IFN-γ or TNF-α signaling show resistance to MPTP-induced neurodegeneration ([@B175]; [@B128]). Mice treated with MPTP show T-cell (CD4^+^) infiltration into the substantia nigra and the MPTP-induced dopaminergic neuron loss is attenuated in T-cell deficient mice suggesting a pro-inflammatory role for T-cells (CD4^+^) in MPTP neurotoxicity ([@B18]). In addition, treatment with anti-inflammatory agents such as minocycline ([@B45]), ibuprofen ([@B182]), flavonoid pycnogenol ([@B93]) and peptide carnosine ([@B188]) and inhibition of pro-inflammatory mediators ([@B194]; [@B205]), reduce inflammation and prevent neurodegeneration in MPTP animal models.

Regulators of Microglial Activation States
==========================================

Microglial activation, astrogliosis and invasion of activated peripheral immune cells trigger deleterious events in the brain that lead to neuronal loss and progression of PD ([@B80]). These observations led to several animal studies and clinical trials to test a variety of established anti-inflammatory molecules (see **Table [2](#T2){ref-type="table"}**). Acetylsalicylic acid, a COX-1/COX-2 inhibitor, exhibits neuroprotective effects in *in vitro* and in MPTP animal models of PD ([@B185]). A prospective clinical study shows that consumption of non-aspirin NSAIDs may delay or prevent the onset of PD ([@B28]). A Cochrane collaboration study which analyzed several prevention trials and observational anti-inflammatory studies reveals that while ibuprofen use might reduce the risk of developing PD, there is no existing evidence that supports NSAID use in PD prevention ([@B158]). A clinical study in PD cases shows an association between use of ibuprofen and lesser PD risk. However, this association is not shared by other NSAIDs studied ([@B60]). Similarly, minocycline, a tetracycline antibiotic that showed promising anti-inflammatory properties in PD animal models ([@B45]; [@B76]; [@B199]), did not provide any symptomatic improvement in PD patients ([@B136]). See **Table [2](#T2){ref-type="table"}** for the list of anti-inflammatory agents studied in PD. Hence, NSAID use appears to provide benefits in PD susceptibility in some cases ([@B192]; [@B163]; [@B58]; [@B176]), however, this beneficial effect of NSAIDs were not replicated in several other studies ([@B169]; [@B15]; [@B163]; [@B7]). One study even suggests that anti-inflammatory drug treatment may be detrimental if given at the later stage of the disease ([@B92]). This therapeutic approach aiming to counteract general neuroinflammation has failed in several disease therapies as reviewed elsewhere ([@B144]). Collectively, these studies indicate that the non-specific inflammatory blockade is unlikely to be beneficial for the disease treatment. Concurrently, the data on the dual role of microglial activation has led to the emergence of the novel therapeutic strategy in other inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, and multiple sclerosis (MS) ([@B157]; [@B17]; [@B197]; [@B137]). This approach of the M1 to the M2 phenotype shift might be beneficial in neuroprotection compared to completely blocking microglial activation through anti-inflammatory drugs. Hence, a more reasonable approach of more specific treatment related to the M1/M2 activation stage by inhibiting the M1 responses and/or promoting the shift of M1 to M2 phenotypic responses is necessary in PD.

###### 

NSAIDs and other anti-inflammatory agents in PD models and clinical trials.

  Molecule               PD model                  Mechanism                             Response                                                                              Reference
  ---------------------- ------------------------- ------------------------------------- ------------------------------------------------------------------------------------- -------------------------------------------
  Ibuprofen              Mouse MPTP                Anti-inflammatory                     Prevent striatal-TH loss                                                              [@B182]
                         Clinical trial            Anti-inflammatory                     Reduce PD risk                                                                        [@B60]
                                                                                                                                                                               
  Acetylsalicylic acid   Mouse MPTP                COX-1/COX-2 inhibitor                 Attenuate loss of nigral DA-neurons, striatal dopamine and locomotor activity         [@B185]
                                                                                                                                                                               
  NSAIDs                 Clinical trials           Anti-inflammatory                     Delay or prevent onset of PD                                                          [@B28]; [@B192]; [@B163]; [@B58]; [@B176]
                         Clinical trials           Anti-inflammatory                     Exacerbate PD symptoms/Does NOT improve PD risk                                       [@B169]; [@B15]; [@B163]; [@B7]
                                                                                                                                                                               
  Minocycline            Mouse MPTP Mouse 6-OHDA   Anti-inflammatory Anti-inflammatory   Attenuate loss of nigral DA-neurons and striatal dopamine Protect TH-positive cells   [@B45]; [@B199]; [@B76]
                         Clinical trial            Anti-inflammatory                     Does NOT improve PD symptoms                                                          [@B136]
                                                                                                                                                                               

COX, cyclooxygenase; DA, dopamine; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NSAIDs, non-steroidal anti-inflammatory drugs; TH, tyrosine hydroxylase.

Targeting M1 Polarization State: Inhibition of Pro-inflammatory M1 Phenotype
----------------------------------------------------------------------------

M1 activation of microglia results in a pro-inflammatory and pro-killing output. To inhibit the pro-inflammatory damage through M1 activation of microglia, its downstream signaling pathways could be targeted. M1 phenotype is induced by IFN-γ via the JAK/STAT signaling pathway and targeting this pathway may arrest M1 activation. In fact, studies show that inhibition of the JAK/STAT pathway leads to suppression of the downstream M1-associated genes in several disease models including experimental allergic encephalomyelitis models and myeloproliferative neoplasms ([@B107]; [@B116]). Another approach to suppress M1 activation would be to target the pro-inflammatory cytokines such as TNF-α, IL-1β and IFN-γ, and decrease its ability to interact with its receptors on other cell types. TNF has been targeted through different approaches in PD animal models to suppress M1-associated toxicity. A single injection of lentivirus-expressing dominant negative TNF (DN-TNF) into the rat substantia nigra concomitantly with 6-hydroxydopamine (6-OHDA) lesion in the striatum attenuates dopaminergic neuron loss and behavioral anomalies in rats ([@B117]). In another study intended to examine the role of TNF in delayed and progressive neurodegeneration model, rats administered with DN-TNF in the substantia nigra 2 weeks after the 6-OHDA lesion show no further dopaminergic neuron loss even after 5 weeks of 6-OHDA suggesting that TNF is an essential mediator of inflammation and hence a promising therapeutic target in PD ([@B73]). In addition, adeno-associated virus (AAV)-mediated transduction of dopaminergic neurons with human ras homolog enriched in brain with S16H mutation, \[hRheb(S16H)\], attenuates nigrostriatal toxicity in 6-OHDA rat model of PD ([@B96], [@B97]). This protective effect is mediated by the production of cAMP response element-binding protein (p-CREB), glial cell line-derived neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF) in unilateral MPP^+^ neurotoxin PD model ([@B131]).

PPARs are actively involved in microglial activation and inflammatory pathways. PPAR agonists are postulated to be beneficial for PD and other neurodegenerative diseases ([@B1]). The administration of a PPARγ agonist, rosiglitazone, arrests degeneration in both striatum and SNpc by decreasing TNF-α production and modulating microglial polarization in MPTPp (MPTP + probenecid) progressive mouse model of PD ([@B24]; [@B148]). Pioglitazone, a PPARγ agonist, prevents tyrosine hydroxylase (TH)-positive neuron loss in substantia nigra and partially averts striatal DA loss in MPTP mice model of PD. Pioglitazone treatment decreases microglial activation, iNOS production and nitric oxide-mediated toxicity in both striatum and substantia nigra ([@B42]). However, a recent clinical trial concluded that pioglitazone did not modify progression in early PD ([@B135]). On the other hand, pioglitazone and rosiglitazone are currently being evaluated in clinical trials for its potential to reduce progression of AD. In addition, treatment of LPS/IFN-γ-activated neuronal and glial cultures with a PPARγ endogenous ligand, 15-deoxy-Δ^12,14^-prostaglandin J~2~, inhibits pro-inflammatory response through the CD200-CD200R1 dependent mechanism ([@B44]). Unpublished data from our group show that administration of a PPAR agonist protects dopaminergic neurons in SNpc and neurites in striatum in MPTP mouse model of PD. This PPAR agonist reduces LPS-induced M1-associated pro-inflammatory cytokine IL-1β in BV2 cells and primary astrocytes in a PPARα-independent manner. Thus, PPAR agonists are potential molecules for curing PD through their property to inhibit M1 microglia-induced neuroinflammation.

Alterations in expression of cannabinoid receptors and endocannabinoid concentrations are illustrated in PD pathogenesis ([@B61]). The endocannabinoid system includes the cannabinoid receptors CB1 and CB2, the endogenous ligands (anandamide and 2-arachidonoylglycerol, 2-AG), and their regulatory enzymes. CB1 receptors are abundant in neurons whereas CB2 receptors are most specifically expressed in glia ([@B139]; [@B102]; [@B53]; [@B170]). The expression of CB2 receptors significantly increases during microglial activation ([@B114]; [@B202]) and CB2 receptors are reported to be localized in substantia nigra, and significantly downregulated in PD patients ([@B61]). A naturally occurring CB2 receptor agonist, β-caryophyllene (BCP), prevented nigral DA-neuron and striatal-TH loss, reduced glial activation and inhibited pro-inflammatory cytokines in rat rotenone model of PD ([@B86]). Another study shows that a non-selective cannabinoid agonist protects loss of DA-neurons in the substantia nigra and DA in the striatum of MPTP intoxicated mice. In addition, this cannabinoid agonist also reduces MPTP-induced motor deficits and microglial activation ([@B151]). Modification of the endocannabinoid system, to reduce pro-inflammatory toxicity, may provide a novel therapeutic avenue for PD treatment.

Tanshinone-I, a bioactive flavonoid, reduces the production of M1-pro-inflammatory mediators (nitric oxide, TNF-α, IL-6 and IL-1β) and, inhibits G-CSF and NF-κB expression after LPS-induced inflammation in BV2 microglial cell lines. In the MPTP mouse model of PD, Tanshinone-I prevents dopaminergic neurotoxicity, improves motor deficits and striatal neurotransmitters ([@B193]). Ghrelin, a stomach-derived endogenous ligand for growth hormone secretagogue receptor 1a (GHS-R1a), prevents loss of nigral dopaminergic neurons and striatal neurites, and improves motor performance in MPTP mouse model of PD. Ghrelin reduces toxicant-induced microglial activation, production of pro-inflammatory cytokines (IL-1β, TNF-α) and iNOS levels in MPTP mice ([@B87]; [@B125]). Piperine, a naturally occurring bioactive molecule, attenuates the loss of TH-positive neurons in the substantia nigra and MPTP-induced motor anomalies. In addition, piperine decreases MPTP-induced microglial activation, pro-inflammatory IL-1β expression and apoptosis in these mice ([@B201]). See **Table [3](#T3){ref-type="table"}** for the summary of other potential molecules that act by inhibiting M1 activation in PD models.

###### 

Molecules targeting microglia activation in PD animal models and clinical trials.

  Molecule                                               PD model                          Mechanism                                      Response                                                                          Reference
  ------------------------------------------------------ --------------------------------- ---------------------------------------------- --------------------------------------------------------------------------------- ---------------------
  Pioglitazone                                           Mouse MPTP                        Inhibit M1 phenotype                           Prevent loss of nigral DA-neurons and partial striatal neurites                   [@B42]
                                                         Clinical trial                    Inhibit M1 phenotype                           Does NOT modify progression in early PD                                           Investigators, 2015
                                                                                                                                                                                                                            
  Rosiglitazone                                          Mouse MPTPp (MPTP + probenecid)   Inhibit M1 phenotype and induce M2 phenotype   Prevent loss of nigral DA-neurons and striatal neurites                           [@B24]; [@B148]
                                                                                                                                                                                                                            
  Lentivirus-expressing dominant negative TNF (DN-TNF)   Rat 6-OHDA (concomitant model)    Inhibit M1-TNF                                 Prevent nigral DA-neuron loss and behavior deficits                               [@B117]
                                                                                                                                                                                                                            
  Lentivirus-expressing DN-TNF                           Rat 6-OHDA (delayed model)        Inhibit M1-TNF                                 Prevent progressive nigral DA-neuron loss                                         [@B73]
                                                                                                                                                                                                                            
  AAV-expressing human IL-10                             Mouse MPTP                        Induce M2 phenotype                            Prevent loss of striatal dopamine and TH                                          [@B168]; [@B89]
                                                                                                                                                                                                                            
  Glatiramer acetate                                     Mouse MPTP                        Induce M2 phenotype                            Prevent loss of nigral DA-neurons                                                 [@B9]; [@B20]
                                                                                                                                                                                                                            
  Endocannabinoid ligand 2-AG enhancer                   Mouse MPTPp                       Induce M2 phenotype                            Prevent loss of striatal dopamine and TH                                          [@B53]
                                                                                                                                                                                                                            
  Tanshinone-I                                           Mouse MPTP                        Inhibit M1 phenotype                           Prevent nigral DA-neuron loss and motor deficits                                  [@B193]
                                                                                                                                                                                                                            
  β-Caryophyllene                                        Rat-rotenone                      Inhibit M1 phenotype                           Prevent loss of nigral DA-neurons and striatal neurites                           [@B86]
                                                                                                                                                                                                                            
  Atractylenolide-I                                      Mouse MPTP                        Inhibit M1 phenotype                           Attenuate loss of nigral DA-neurons and behavior deficits                         [@B126]
                                                                                                                                                                                                                            
  Loganin                                                Mouse MPTP                        Inhibit M1 phenotype                           Prevent loss of striatal dopamine and TH                                          [@B200]
                                                                                                                                                                                                                            
  α-Asarone                                              Mouse MPTP                        Inhibit M1 phenotype                           Attenuate behavior deficits                                                       [@B95]
                                                                                                                                                                                                                            
  Capsaicin                                              Mouse MPTP                        Inhibit M1 phenotype                           Attenuate loss of nigral DA-neurons, striatal dopamine, and behavioral deficits   [@B33]
                                                                                                                                                                                                                            
  Isobavachalcone                                        Mouse MPTP                        Inhibit M1 phenotype                           Attenuate behavior deficits and neuronal necrosis                                 [@B88]
                                                                                                                                                                                                                            
  Vitamin-D                                              Mouse MPTP                        Inhibit M1 phenotype and induce M2 phenotype   Prevent loss of TH-positive neurons                                               [@B22]
                                                                                                                                                                                                                            
  Mitoapocynin                                           Mouse MPTP                        Inhibit M1 phenotype                           Attenuate loss of nigral DA-neurons, striatal dopamine and behavioral deficits    [@B65]
                                                                                                                                                                                                                            
  Ginsenoside Rg1                                        Mouse MPTPp                       Inhibit M1 phenotype                           Attenuate loss of nigral DA-neurons and behavior deficits                         [@B77]
                                                                                                                                                                                                                            

AAV, adeno-associated virus; DA, dopamine; IL, interleukin; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 6-OHDA, 6-hydroxydopamine; TH, tyrosine hydroxylase; TNF, tumor necrosis factor.

Targeting M2 Polarization State
-------------------------------

The molecules with the capability to activate the anti-inflammatory M2 phenotype or promote the transition of pro-inflammatory M1 phenotype to anti-inflammatory M2 could be useful in the treatment of PD. Anti-inflammatory molecules such as IL-10 and beta interferons produce neuroprotection by altering the M1 and M2 balance. Cerebral infusion of AAV-expressing human IL-10 in a MPTP mouse model of PD decreases the expression of pro-inflammatory iNOS and importantly enhances the levels of anti-inflammatory mediators including IFN-γ and transforming growth factor-β (TGF-β). Infusion of AAV-expressing human IL-10 prevents the loss of striatal DA and reduces TH transcriptome levels suggesting neuroprotection in MPTP intoxicated mice ([@B168]; [@B89]).

Treatment with pioglitazone, a PPARγ agonist, causes a phenotypic conversion of microglia from the pro-inflammatory M1 state to the anti-inflammatory M2 state. This conversion is strongly linked to increase in phagocytosis of misfolded protein deposits resulting in the reduction of amyloid levels and an associated reversal of contextual memory deficits in AD mice ([@B113]). As mentioned before, pioglitazone treatment decreases microglial activation, iNOS production and NO-mediated nigrostriatal toxicity in MPTP mouse model ([@B42]).

The endocannabinoid system is implicated in PD pathogenesis ([@B61]). In a chronic MPTPp model of PD, the administration of an inhibitor that prevents degradation of 2-AG (JZL184), an endocannabinoid ligand, prevents MPTPp-induced motor impairment and protects the nigrostriatal pathway ([@B53]). MPTPp mice treated with JZL184 exhibits microglial phenotypic changes and restorative microglial activation along with increased TGF-β and GDNF levels.

Glatiramer acetate is a Food and Drug Administration (FDA) approved drug for MS treatment ([@B50]) and its neuroprotective effect is mediated by activation of the microglial M2 phenotype ([@B67]). Glatiramer acetate protects dopaminergic neurons in a MPTP mouse model by helping the recruitment of T lymphocytes in the SN, while inhibiting microglial activation and upregulation of GDNF expression ([@B9]; [@B20]). Glatiramer acetate also exhibits neuroprotection in Alzheimer's disease animal models where its treatment induces microglial co-localization with amyloid fibrils and a switch in microglial phenotype that produces insulin like growth factor 1 ([@B21]). Dimethyl fumarate (DMF), an approved drug for MS treatment, protects against the depletion of striatal DA and its transporters and, reduces MPTP-induced increase in IL-1β and COX-2 activity in MPTP mouse model of PD. DMF also modulates microglial activation states and restores nerve growth factor levels to provide neuroprotection in MPTP-intoxicated mice ([@B23]). Other molecules that are reported to possess neuroprotective properties by inducing M2 microglial activation are listed in **Table [3](#T3){ref-type="table"}**.

Novel Microglial Targets
========================

Other novel potential microglial targets for immunomodulation are reviewed elsewhere ([@B144]). These approaches include the following targets: (1) 5′ adenosine monophosphate-activated protein kinase (AMPK): a critical enzyme in cellular energy homeostasis, (2) microglia-produced high-mobility group box-1 (HMGB1): an early released pro-inflammatory cytokine, (3) glycogen synthase kinase-3β (GSK3β): an enzyme that mediates microglial migration and inflammation-induced neurotoxicity, and (4) histone deacetylases (HDACs).

Concluding Remarks and Future Directions
========================================

The critical role of microglia in most neurodegenerative pathologies including PD is increasingly documented through many studies. Until recently, microglial activation in pathological conditions was considered to be detrimental to neuronal survival in the substantia nigra of PD brains. Recent findings highlight the crucial physiological and neuroprotective role of microglia and other glial cells in neuropathological conditions. Studies on anti-inflammatory treatments targeting neuroinflammation in PD and other diseases by delaying or blocking microglial activation failed in many trials due to the lack of a specific treatment approach, possibly the stage of disease and an incorrect understanding of mechanisms underlying microglial activation. With the updated knowledge on different microglial activation states, drugs that can shift microglia from a pro-inflammatory M1 state to anti-inflammatory M2 state could be beneficial for PD. The M1 and M2 microglial phenotypes probably need further characterization, particularly in PD pathological conditions for better therapeutic targeting. We support targeting of microglial cells by modulating their activation states as a novel therapeutic approach for PD.
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